Cite
Warthaka M, Adelmann CH, Kaoud TS, et al. Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Med Chem Lett. 2014;6(1):47-52doi: 10.1021/ml500198b.
Warthaka, M., Adelmann, C. H., Kaoud, T. S., Edupuganti, R., Yan, C., Johnson, W. H., Ferguson, S., Tavares, C. D., Pence, L. J., Anslyn, E. V., Ren, P., Tsai, K. Y., & Dalby, K. N. (2015). Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS medicinal chemistry letters, 6(1), 47-52. https://doi.org/10.1021/ml500198b
Warthaka, Mangalika, et al. "Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine." ACS medicinal chemistry letters vol. 6,1 (2015): 47-52. doi: https://doi.org/10.1021/ml500198b
Warthaka M, Adelmann CH, Kaoud TS, Edupuganti R, Yan C, Johnson WH, Ferguson S, Tavares CD, Pence LJ, Anslyn EV, Ren P, Tsai KY, Dalby KN. Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Med Chem Lett. 2014 Oct 17;6(1):47-52. doi: 10.1021/ml500198b. eCollection 2015 Jan 08. PMID: 25589929; PMCID: PMC4291693.
Copy
Download .nbib